» Articles » PMID: 31184216

Analysis of MiRNA-mRNA Network Reveals MiR-140-5p As a Suppressor of Breast Cancer Glycolysis Via Targeting GLUT1

Overview
Journal Epigenomics
Specialty Genetics
Date 2019 Jun 12
PMID 31184216
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Aerobic glycolysis is characteristic of breast cancer. Comprehensive expression profiles of key proteins, their prognosis and detailed relationships between miRNAs and mRNAs remain unclear. Oncomine database, Kaplan-Meier overall survival and miRNA-mRNA network analysis were performed. A key miRNA was identified and explored and . Eleven key glycolytic proteins were found with higher expression and poor prognosis: GLUT1, SLC2A5, HK1, PFKP, ALDOA, TPI1, GAPDH, PGK1, ENO1, GOT1 and GOT2. Seven miRNAs were predicted targeting 11 key glycolytic proteins: miR-140-5p, miR-3064-5p, miR-152-3p, miR-449b-5p, miR-449a, miR-194-5p and miR-34a-5p. Among them, miR-140-5p was found to be downregulated in breast cancer and directly targeted GLUT1, resulting in an antiglycolytic and antiproliferative effect.

Citing Articles

The role of GOT1 in cancer metabolism.

Peng H, Dou H, He S, Xie Y, Zhang Q, Zheng J Front Oncol. 2025; 14():1519046.

PMID: 39777342 PMC: 11703747. DOI: 10.3389/fonc.2024.1519046.


SIRT1 maintains bone homeostasis by regulating osteoblast glycolysis through GOT1.

Jin X, Sun X, Ma X, Qin Z, Gao X, Kang X Cell Mol Life Sci. 2024; 81(1):204.

PMID: 38700532 PMC: 11072260. DOI: 10.1007/s00018-023-05043-9.


Transcriptional regulation and post-translational modifications in the glycolytic pathway for targeted cancer therapy.

Ni X, Lu C, Xu G, Ma J Acta Pharmacol Sin. 2024; 45(8):1533-1555.

PMID: 38622288 PMC: 11272797. DOI: 10.1038/s41401-024-01264-1.


LncRNA OIP5-AS1 Targets the miR-140-5p/UBR5 Cascade to Promote the Development of Gastric Cancer.

Liu M, Song X, Sun Y, Zhang T Mol Biotechnol. 2023; 66(12):3583-3596.

PMID: 38112962 DOI: 10.1007/s12033-023-00958-x.


Spotlight on GOT2 in Cancer Metabolism.

Kerk S, Garcia-Bermudez J, Birsoy K, Sherman M, Shah Y, Lyssiotis C Onco Targets Ther. 2023; 16:695-702.

PMID: 37635751 PMC: 10460182. DOI: 10.2147/OTT.S382161.